<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03250299</url>
  </required_header>
  <id_info>
    <org_study_id>ABTC 1601</org_study_id>
    <secondary_id>CDI-CS-004</secondary_id>
    <secondary_id>IRB00131687</secondary_id>
    <nct_id>NCT03250299</nct_id>
  </id_info>
  <brief_title>Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma</brief_title>
  <official_title>Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL101553 in Combination With Standard Radiation in Patients With MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Basilea Pharmaceutica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Basilea Pharmaceutica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of microtubule-targeted agent&#xD;
      BAL101553 when given together with radiation therapy in treating patients with newly&#xD;
      diagnosed glioblastoma. Drugs used in chemotherapy, such as microtubule-targeted agent&#xD;
      BAL101553, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy&#xD;
      uses high-energy x-rays to kill tumor cells and shrink tumors. Giving microtubule-targeted&#xD;
      agent BAL101553 and radiation therapy may work better in treating patients with glioblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximum tolerated dose of microtubule-targeted agent BAL101553&#xD;
      (BAL101553) in combination with standard radiation in patients with newly diagnosed MGMT&#xD;
      promoter unmethylated glioblastoma (GBM).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate safety and tolerability of the combination of BAL101553 in combination with&#xD;
      standard radiation in patients with newly diagnosed MGMT promoter unmethylated GBM.&#xD;
&#xD;
      II. To determine overall and progression-free survival. III. To assess the pharmacokinetics&#xD;
      of BAL101553 and BAL27862. IV. To explore expression of biomarkers, including BubR1, stathmin&#xD;
      and EB1 at baseline (exploratory biomarkers).&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of the microtubule-targeted agent BAL101553.&#xD;
&#xD;
      Patients receive microtubule-targeted agent BAL101553 orally (PO) once daily (QD) on days&#xD;
      1-42 and undergo concomitant standard radiation therapy 5 days per week for 6 weeks in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 30 days, and then every 2&#xD;
      months for 2 years and then every 6 months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2017</start_date>
  <completion_date type="Anticipated">June 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>up to 10 weeks</time_frame>
    <description>Number of Dose limited Toxicities per dose level. ANC &lt; 500/mm3; Platelets &lt; 25K; Febrile neutropenia; any event which prevents 80% administration of planned BAL101553 dose; &gt;/= gr 2 CNS ischemia; &gt;/= gr 2 neurological toxicities interfering with AODL not resolved within 2wks; gr 3/4 non-hematological, non-CNS toxicities with expections</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with Grade 3 and Grade 4 AEs</measure>
    <time_frame>up to 10 weeks</time_frame>
    <description>CTC AE 4.0 / 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>initial diagnosis to date of death - up to 2 years</time_frame>
    <description>Median time of survival along with 95% confidence interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>initial diagnosis to date of progression - up to 2 years</time_frame>
    <description>Median time of progression-free survival along with 95% confidence interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4, 6, and 24 hours post dose on days 1 and 22</time_frame>
    <description>PK of microtubule-targeted agent BAL101553 and BAL27862</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Plasma Concentraion</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4, 6, and 24 hours post dose on days 1 and 22</time_frame>
    <description>PK of microtubule-targeted agent BAL101553 and BAL27862</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve (AUC)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4, 6, and 24 hours post dose on days 1 and 22</time_frame>
    <description>PK of microtubule-targeted agent BAL101553 and BAL27862</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Half-life</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4, 6, and 24 hours post dose on days 1 and 22</time_frame>
    <description>PK of microtubule-targeted agent BAL101553 and BAL27862</description>
  </other_outcome>
  <other_outcome>
    <measure>Clearance and Volume</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4, 6, and 24 hours post dose on days 1 and 22</time_frame>
    <description>PK of microtubule-targeted agent BAL101553 and BAL27862</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Glioblastoma</condition>
  <condition>MGMT-Unmethylated Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Dose Finding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed 3+3 dose escalation of BAL101553 (7 days per week), combined with RT days 1-5 for 6 weeks followed by 4 week rest.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAL101553 at the MTD / highest dose considered safe (7 days per week), combined with RT days 1-5 for 6 weeks followed by 4 week rest.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Microtubule-Targeted Agent BAL101553</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Dose Finding</arm_group_label>
    <arm_group_label>Expansion Cohort</arm_group_label>
    <other_name>BAL101553, Microtubule-targeted Agent BAL101553</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Undergo radiation therapy</description>
    <arm_group_label>Dose Finding</arm_group_label>
    <arm_group_label>Expansion Cohort</arm_group_label>
    <other_name>Cancer Radiotherapy, Irradiate, irradiated, irradiation, RADIATION, Radiation, radiation therapy, Radiation Therapy, Radiotherapeutics, radiotherapy, Radiotherapy, RT, Therapy, Radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Dose Finding</arm_group_label>
    <arm_group_label>Expansion Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Dose Finding</arm_group_label>
    <arm_group_label>Expansion Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically-proven GBM&#xD;
&#xD;
          -  Patients must have recovered from the immediate post-operative period&#xD;
&#xD;
          -  Patients must have tumor MGMT methylation status of unmethylated as determined by&#xD;
             local pathologist using a Clinical Laboratory Improvement Act (CLIA)-approved&#xD;
             diagnostic test; results of routinely-used methods for MGMT methylation testing (e.g.&#xD;
             methylation-specific [MS]- polymerase chain reaction [PCR] or quantitative PCR) are&#xD;
             acceptable&#xD;
&#xD;
          -  Patients must be able to undergo magnetic resonance imaging (MRI) of the brain with&#xD;
             gadolinium&#xD;
&#xD;
          -  Patients must not have received prior radiation therapy (RT), chemotherapy,&#xD;
             immunotherapy or therapy with a biologic agent (including immunotoxins,&#xD;
             immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins,&#xD;
             tumor-infiltrating lymphocytes, lymphokine-activated killer cells, or gene therapy),&#xD;
             or hormonal therapy for their brain tumor; glucocorticoid therapy is allowed&#xD;
&#xD;
          -  Patients must have a tumor tissue form indicating availability of archived tissue from&#xD;
             initial resection at diagnosis of GBM, completed and signed by a pathologist&#xD;
&#xD;
          -  Patients must have a Karnofsky performance status &gt;= 60% (i.e. the patient must be&#xD;
             able to care for himself/herself with occasional help from others)&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mcL&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mcL&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dL&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x institutional upper limit of normal (ULN), unless the patient&#xD;
             has known Gilbert's syndrome&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
             =&lt; 2.5 x ULN&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 x ULN&#xD;
&#xD;
          -  Creatinine clearance &gt;= 60 mL/min/1.73 m^2 for patients with creatinine levels &gt; ULN&#xD;
&#xD;
          -  Activated partial thromboplastin time (APTT)/partial thromboplastin time (PTT) =&lt; 1.5&#xD;
             x ULN&#xD;
&#xD;
          -  Sodium &gt;= 130 mmol/L&#xD;
&#xD;
          -  Patients must be able to provide written informed consent&#xD;
&#xD;
          -  Patients must have baseline MRI performed within the 21 days prior to starting&#xD;
             treatment&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test within 72&#xD;
             hours prior to the first dose of BAL101553; women of childbearing potential must agree&#xD;
             to use highly-effective contraceptive methods for the duration of study participation&#xD;
             and for an additional 90 days after the last dose of study drug; highly-effective&#xD;
             contraceptive methods include male or female sterilization (bilateral tubal occlusion&#xD;
             or vasectomy); intrauterine device (IUD); combined (estrogen- and&#xD;
             progesterone-containing) hormonal contraception (oral, vaginal ring or transdermal&#xD;
             patch) with an ethinylestradiol dose of at least 30 ug, plus use of male condoms&#xD;
             (preferably with spermicides), female condoms, a female diaphragm or a cervical cap;&#xD;
             or total sexual abstinence; should a woman become pregnant or suspect she is pregnant&#xD;
             while participating in this study, she should inform her treating physician&#xD;
             immediately; male patients must agree not to donate sperm from the first dose of study&#xD;
             drug until 90 days after the end of treatment; male patients, without a vasectomy and&#xD;
             with a partner of childbearing potential, must agree to use condoms during the study&#xD;
             and for at least 90 days after the end of treatment; the patient should be instructed&#xD;
             that their female partner should use another form of contraception for the duration of&#xD;
             the study and continue this use for at least 90 days after the last dose of study drug&#xD;
&#xD;
          -  Patients must have no concurrent malignancy except curatively treated basal or&#xD;
             squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or&#xD;
             bladder; patients with prior malignancies must be disease-free for &gt;= 5 years&#xD;
&#xD;
          -  Patients must be maintained on a stable corticosteroid regimen (no increase for 5&#xD;
             days) prior to the start of treatment&#xD;
&#xD;
          -  Patients must be able to swallow whole capsules&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients receiving any other investigational agents&#xD;
&#xD;
          -  Patients with a history of allergic reactions attributed to compounds of similar&#xD;
             chemical or biologic composition to BAL101553&#xD;
&#xD;
          -  Patients on drugs that are strong inhibitors and/or inducers of CYP2C9, CYP2C19 or&#xD;
             CYP3A4 (including enzyme-inducing anti-epileptic drugs [EIAEDs]), are not eligible for&#xD;
             treatment under this protocol; patients taking non-EIAEDs are permitted to take part&#xD;
             in the study; patients previously treated with any of the prohibited concomitant&#xD;
             medications listed above may be enrolled if they have been off of the medication for&#xD;
             &gt;= 10 days prior to the first dose of BAL101553&#xD;
&#xD;
          -  Patients may not be on coumarin anti-coagulants (warfarin, etc.); heparin,&#xD;
             low-molecular weight heparin (LMWH), or other antithrombotic medications are permitted&#xD;
&#xD;
          -  Patients with gastrointestinal disease, or those who have had a procedure that is&#xD;
             expected to interfere with the oral absorption or tolerance of BAL101553 (e.g.,&#xD;
             functionally-relevant gastrointestinal obstruction, or frequent vomiting unresolved&#xD;
             upon anti-emetic supportive care)&#xD;
&#xD;
          -  Patients with peripheral neuropathy &gt;= Common Terminology Criteria for Adverse Events&#xD;
             (CTCAE) grade 2&#xD;
&#xD;
          -  Patients with ataxia &gt;= CTCAE grade 2&#xD;
&#xD;
          -  Patients with known acute or chronic hepatitis B or hepatitis C infection \&#xD;
&#xD;
          -  Patients with systolic blood pressure (SBP) &gt;= 140 mmHg or diastolic blood pressure&#xD;
             (DBP) &gt;= 90 mmHg at the screening visit are ineligible; patients with an initial&#xD;
             clinic blood pressure (BP) &gt;= 140/90 mmHg may be included if SBP &lt; 140 mmHg and DBP &lt;&#xD;
             90 mmHg is confirmed in two subsequent BP measurements on the same day&#xD;
&#xD;
          -  Patients with blood pressure (BP) combination treatment with more than two&#xD;
             antihypertensive medications are ineligible&#xD;
&#xD;
          -  Significant cardiac disease or abnormality, including any one of the following:&#xD;
&#xD;
               -  Left ventricular ejection fraction &lt; 50% at screening (assessed by&#xD;
                  echocardiography, cardiac MRI or multigated acquisition [MUGA])&#xD;
&#xD;
               -  Corrected QT Fridericia's correction formula (QTcF) &gt; 470 ms on screening&#xD;
                  electrocardiogram (ECG), or a clinically-relevant ECG abnormality&#xD;
&#xD;
               -  Congenital long QT syndrome&#xD;
&#xD;
               -  History of sustained ventricular tachycardia, ventricular fibrillation, or&#xD;
                  torsades de pointes&#xD;
&#xD;
               -  Presence of atrial fibrillation with tachyarrhythmia (ventricular response rate &gt;&#xD;
                  100 beats per minute [bpm])&#xD;
&#xD;
               -  Bradycardia (heart rate &lt; 50 bpm)&#xD;
&#xD;
               -  Complete left bundle branch block.&#xD;
&#xD;
               -  Bifascicular block (complete right bundle branch block and anterior or posterior&#xD;
                  left hemiblock)&#xD;
&#xD;
               -  Myocardial infarction, acute coronary syndrome (including unstable angina),&#xD;
                  coronary revascularization procedures, or coronary arterial bypass grafting&#xD;
                  within the 6 months prior to starting study drug&#xD;
&#xD;
               -  Cardiac troponin (either troponin T or troponin I) &gt; ULN&#xD;
&#xD;
               -  Congestive heart failure of New York Heart Association class III or IV&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
          -  Patients with uncontrolled intercurrent illness including, but not limited to, ongoing&#xD;
             or active infection or psychiatric illness/social situations that would limit&#xD;
             compliance with study requirements, are ineligible&#xD;
&#xD;
          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if&#xD;
             the mother is treated with BAL101553&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral&#xD;
             therapy are ineligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Holdhoff, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias Holdhoff, MD</last_name>
    <phone>410-955-8837</phone>
    <email>mholdho1@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joy Fisher, MA</last_name>
    <phone>410-955-8837</phone>
    <email>jfisher@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UAB Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thiru Pillay, RN</last_name>
      <phone>205-934-1842</phone>
      <email>thiru@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Burt Nabors, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Holdhoff, MD</last_name>
      <phone>410-955-3657</phone>
      <email>mholdho1@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michaella Iacoboni, RN</last_name>
      <phone>410-955-4009</phone>
      <email>msheeh13@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Matthias Holdhoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Dana-Farber/Harvard Cancer Center</last_name>
      <phone>617-632-2166</phone>
    </contact>
    <contact_backup>
      <last_name>Wen</last_name>
    </contact_backup>
    <investigator>
      <last_name>Patrick Wen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Williamson, RN</last_name>
      <email>awillia12@hfhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Emily Krozek, MHSA</last_name>
      <email>ekrozek1@hfhs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Tobias Walbert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office</last_name>
      <phone>336-713-6771</phone>
    </contact>
    <contact_backup>
      <last_name>Roy Strowd</last_name>
      <phone>336-716-2357</phone>
    </contact_backup>
    <investigator>
      <last_name>Roy Strowd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Center-Cares</last_name>
      <phone>216-444-7923</phone>
    </contact>
    <investigator>
      <last_name>Manmeet Ahluwalia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Peereboom, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abrams Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Prior</last_name>
      <phone>215-615-3673</phone>
      <email>NCRD-BTC@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Arati Desai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hillman Cancer Center at University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - UPMC Cancer Centers</last_name>
      <phone>412-647-8073</phone>
    </contact>
    <investigator>
      <last_name>Frank Lieberman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 28, 2017</study_first_submitted>
  <study_first_submitted_qc>August 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2017</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

